MedTrace Logo

Initiating Pediatric Palliative Care in ACT Group 4

NCT06273267 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 126

Last updated 2025-09-12

No results posted yet for this study

Summary

Due to the wide range of diagnoses encountered in pediatric palliative care, the Association for Children's Palliative Care (ACT) and the Royal College of Paediatrics and Child Health (RCPCH) have developed a classification of life-limiting illnesses, based on support models.

This classification includes four groups. ACT 4 category is made up of children with a serious incurable non-progressive neurological disease (for example: anoxic ischemia, cerebral palsy, traumatic or infectious brain injuries).

Although data relating to specific ACT groups are scarce, experience from clinical practice suggests that the needs and use of Pediatric palliative care resources are different across the four categories.

The specific history of ACT-4 patients suggests that pediatric palliative care may be required early on in the history of the disease but effective intervention varies greatly from one patient to another. Tthis study aims to better understand the optimal timing for introducing a PPC team into the care pathway for these children. The study also aims to describe the care trajectory over the first year of PPC intervention.

Conditions

  • Encephalopathy
  • Cerebral Palsy
  • Cerebral Malformation
  • Traumatic Head Injury

Interventions

OTHER

Collection of data from the patient's medical file

Collection of data from the patient's medical file. The data collected concerns the first year of follow-up (from the initial PPC intervention to one year to date post-intervention).

Sponsors & Collaborators

  • URC-CIC Paris Descartes Necker Cochin

    collaborator OTHER

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Ashley RIDLEY, M.D. · Assistance Publique - Hôpitaux de Paris

  • Hélène GEFFROY, Resident · Assistance Publique - Hôpitaux de Paris

Eligibility

Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-22
Primary Completion
2024-07-22
Completion
2024-07-22

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06273267 on ClinicalTrials.gov